When HNSCC xenografts in mice were treated with HER2 and CAR2.CAR-T cells in combination with CAd12-PDL1, the survival rate of the mice was approximately 25 days with either approach, while it was extended to over 100 days by the combined therapy with the control of distant metastasis. Here, ERBB2 is linked to head and neck squamous cell carcinoma.